This page ranks therapeutic approaches and drugs for neurodegenerative diseases based on clinical evidence, FDA approval status, and therapeutic potential.
| Rank | Treatment | Target | Evidence Level | Status |
|------|-----------|--------|----------------|--------|
| 1 | Lecanemab | Amyloid-beta | Phase 3, FDA approved | Available |
| 2 | Donanemab | Amyloid-beta | Phase 3, FDA approved | Available |
| 3 | Aducanumab | Amyloid-beta | Phase 3, FDA approved (accelerated) | Available |
| 4 | Semorinemab | Tau | Phase 2 | Active trials |
| 5 | Gosuranemab | Tau | Phase 2 | Active trials |
| Rank |
Treatment |
Indication |
Efficacy |
| 1 |
Donepezil |
Mild-to-severe AD |
High |
| 2 |
Memantine |
Moderate-to-severe AD |
Moderate |
| 3 |
Rivastigmine |
Mild-to-moderate AD |
Moderate |
| 4 |
Galantamine |
Mild-to-moderate AD |
Moderate |
| 5 |
Namzaric |
Moderate-to-severe AD |
Moderate |
| Rank |
Treatment |
Class |
Motor Benefit |
Side Effects |
| 1 |
Levodopa/Carbidopa |
Dopamine precursor |
Highest |
Dyskinesias |
| 2 |
Pramipexole |
Dopamine agonist |
High |
Impulse control |
| 3 |
Rotigotine |
Dopamine agonist |
High |
Skin reactions |
| 4 |
Rasagiline |
MAO-B inhibitor |
Moderate |
Headache |
| 5 |
Entacapone |
COMT inhibitor |
Moderate |
Diarrhea |
| Rank |
Treatment |
Indication |
Efficacy |
| 1 |
Deep Brain Stimulation |
Motor complications |
High |
| 2 |
Levodopa-carbidopa intestinal gel |
Motor fluctuations |
High |
| 3 |
Apomorphine infusion |
Motor fluctuations |
High |
| 4 |
Duodopa |
Advanced PD |
High |
| Rank |
Treatment |
Mechanism |
Evidence |
Status |
| 1 |
Relyvrio (Sodium Phenylbutyrate/Taurursodiol) |
Dual: ER stress + mitochondrial protection |
Phase 3, FDA approved 2022 |
Available |
| 2 |
Edaravone |
Antioxidant |
Phase 3, FDA approved 2017 |
Available |
| 3 |
Riluzole |
Glutamate inhibition |
Phase 3, FDA approved 1995 |
Available |
| 4 |
Tofersen |
SOD1 gene silencing |
Phase 3, FDA approved 2023 (accelerated) |
Available |
| Rank |
Treatment |
Target |
Evidence |
Status |
| 1 |
Tofersen |
SOD1 mutations |
Phase 3, clinical benefit shown |
Available for SOD1 carriers |
| 2 |
BIIB078 |
C9orf72 |
Phase 1 |
Clinical trial |
| 3 |
ASO targeting FUS |
FUS mutations |
Preclinical |
IND-enabling |
| Rank |
Treatment |
Indication |
Benefit |
| 1 |
Non-invasive ventilation (NIV) |
Respiratory weakness |
Extends survival 7-21 months |
| 2 |
Percutaneous endoscopic gastrostomy (PEG) tube |
Nutritional support |
Maintains weight, improves outcomes |
| 3 |
Speech therapy |
Dysarthria |
Maintains communication |
| 4 |
Physical therapy |
Mobility preservation |
Prevents contractures |
| 5 |
Occupational therapy |
ADL independence |
Improves quality of life |
| Rank |
Treatment |
Symptom |
Evidence |
| 1 |
Baclofen or Tizanidine |
Spasticity |
Standard of care |
| 2 |
Amitriptyline or Glycopyrrolate |
Drooling (sialorrhea) |
Standard of care |
| 3 |
Quinine or Mexiletine |
Muscle cramps |
Moderate evidence |
| 4 |
SSRIs or SNRIs |
Depression/anxiety |
Standard of care |
| 5 |
Lorazepam |
Dyspnea/panic attacks |
Acute management |
| Trial |
Intervention |
Target |
Status |
| HEALEY ALS Platform |
Multiple arms |
Various |
Recruiting |
| CNTN4 |
CNversyt |
Neurotrophic factor |
Phase 3 |
| Masitinib |
Masitinib |
Tyrosine kinase |
Phase 3 |
- Cell therapy: Stem cell transplantation (various trials)
- Gene therapy: AAV-based delivery of protective genes
- Combination therapy: Multi-target approaches in development
- Biomarker-driven trials: Enrolling based on molecular subtypes
| Rank |
Treatment |
Target |
Evidence |
| 1 |
SSRIs |
Behavior |
Moderate |
| 2 |
Trazodone |
Behavior |
Limited |
| 3 |
Valproate |
Agitation |
Limited |
- Amyloid immunotherapies: Continued development
- Tau immunotherapies: Semorinemab, Zagotenemab
- Alpha-synuclein: Prasinezumab, Cinpanemab
- Neuroprotective: Tyrosine kinase inhibitors
- Anti-inflammatory: NLRP3 inhibitors
- Gene therapies: Various targets
- Cell therapies: Stem cell approaches
When selecting treatments, consider:
- Disease stage: Symptomatic vs. disease-modifying
- Genetic factors: APOE status, mutation carriers
- Comorbidities: Cardiovascular, renal, hepatic
- Patient preferences: Delivery method, side effects
- Cost and access: Insurance, geographic availability
| Rank |
Treatment |
Class |
Evidence Level |
Response Rate |
Status |
| 1 |
Levodopa/Carbidopa |
Dopamine precursor |
Limited |
10-30% |
Trial recommended |
| 2 |
Amantadine |
NMDA antagonist |
Limited |
~20% |
Off-label |
| 3 |
Pramipexole |
Dopamine agonist |
Poor |
<10% |
Off-label |
| 4 |
Benztropine |
Anticholinergic |
Limited |
Variable |
Off-label |
| Rank |
Treatment |
Approach |
Evidence |
| 1 |
Prizm lenses |
Prism compensation |
Limited |
| 2 |
Vision therapy |
Oculomotor exercises |
Limited |
| 3 |
Artificial tears |
Ocular lubrication |
Supportive |
| Rank |
Treatment |
Symptom |
Evidence |
| 1 |
SSRIs (Sertraline, Escitalopram) |
Depression/anxiety |
Standard of care |
| 2 |
Methylphenidate |
Apathy |
Limited |
| 3 |
Dextromethorphan/Quinidine |
Pseudobulbar affect |
Moderate |
| 4 |
Modafinil |
Fatigue |
Limited |
| Rank |
Treatment |
Mechanism |
Trial Phase |
Status |
| 1 |
Semorinemab |
Anti-tau antibody |
Phase 2 |
Negative |
| 2 |
Gantenerumab |
Anti-tau antibody |
Phase 2 |
Negative |
| 3 |
Tilavonemab |
Anti-tau antibody |
Phase 2 |
Negative |
| 4 |
AADvac1 |
Tau active vaccine |
Phase 2 |
Mixed results |
| 5 |
LTMX (Leurometaximel) |
Tau aggregation inhibitor |
Phase 2 |
Completed |
| Rank |
Treatment |
Indication |
Benefit |
| 1 |
Physical therapy |
Balance/gait |
Fall prevention |
| 2 |
Occupational therapy |
Daily living |
Safety adaptation |
| 3 |
Speech therapy (LSVT LOUD) |
Voice |
Communication |
| 4 |
Swallowing therapy |
Dysphagia |
Aspiration prevention |
| Agent |
Mechanism |
Phase |
Status |
| Bepranemab |
Anti-tau antibody |
Phase II |
Recruiting |
| Eisoselenomethyl |
Selenoprotein |
Phase I |
Completed |
| Rank |
Treatment |
Indication |
Benefit |
| 1 |
Multidisciplinary team |
Comprehensive care |
Standard of care |
| 2 |
Caregiver support |
Education/resources |
Quality of life |
| 3 |
Environmental modifications |
Safety |
Fall prevention |
| Rank |
Treatment |
Evidence |
Response Rate |
Status |
| 1 |
Levodopa/Carbidopa |
Trial recommended |
10-20% |
Diagnostic trial |
| 2 |
Pramipexole |
Limited |
<10% |
Off-label |
¶ Dystonia and Spasticity
| Rank |
Treatment |
Evidence |
Status |
| 1 |
Botulinum toxin |
Effective for focal |
Available |
| 2 |
Benzodiazepines (Clonazepam) |
Standard of care |
Available |
| 3 |
Baclofen |
Spasticity |
Available |
| Rank |
Treatment |
Dose |
Evidence |
| 1 |
Levetiracetam |
500-1500mg BID |
Standard |
| 2 |
Clonazepam |
0.5-2mg daily |
Standard |
| 3 |
Valproic acid |
500-1500mg daily |
Moderate |
¶ Cognitive and Behavioral Symptoms
| Rank |
Treatment |
Symptom |
Evidence |
| 1 |
Donepezil |
Cognitive |
Limited |
| 2 |
Rivastigmine |
Cognitive |
Limited |
| 3 |
Memantine |
Cognitive |
Mixed |
| 4 |
SSRIs |
Depression/anxiety |
Standard |
| 5 |
Methylphenidate |
Apathy |
Limited |
| 6 |
Quetiapine |
Agitation |
Off-label |
| Rank |
Treatment |
Mechanism |
Trial Phase |
Status |
| 1 |
Bepranemab |
Anti-tau antibody |
Phase II |
Recruiting |
| 2 |
Tilavonemab |
Anti-tau antibody |
Phase II |
Completed |
| 3 |
Gantenerumab |
Anti-tau antibody |
Phase II |
Negative |
| Rank |
Treatment |
Indication |
Benefit |
| 1 |
Physical therapy |
Mobility |
Maintain function |
| 2 |
Occupational therapy |
Alien limb/ADL |
Compensation |
| 3 |
Speech therapy |
Dysarthria/apraxia |
Communication |
| 4 |
Botulinum toxin |
Focal dystonia |
Pain relief |
| Agent |
Mechanism |
Phase |
Status |
| Antisense oligonucleotides |
Tau reduction |
Preclinical |
IND-enabling |
| AAV gene therapy |
Tau reduction |
Preclinical |
Research |
The following neurodegenerative conditions lack dedicated treatment sections:
- Multiple System Atrophy (MSA): No treatment rankings
- Huntington's Disease: Only minimal mention in emerging treatments
- Dementia with Lewy Bodies (DLB): No dedicated section
- Vascular Dementia: No dedicated section
- Amyotrophic Lateral Sclerosis (ALS): Only 3 approved treatments listed - missing newer therapies (Relyvrio/Amylyx, dexpramipexole trials)
- Frontotemporal Dementia: Only 3 symptomatic approaches - no disease-modifying therapies covered
- Disease-modifying therapies for PD: Only symptomatic and advanced therapies covered
- Gene therapies: Only mentioned in Phase 1 - no dedicated ranking
- Cell therapies: Only mentioned in Phase 1 - no dedicated ranking
- Neuroprotective agents: Broad category but no dedicated section
- Combination therapies: No ranking or analysis
- AD: Missing anti-amyloid beyond immunotherapies (e.g., bace inhibitors history)
- PD: Missing newer dopamine agonists (e.g., noloparin)
- ALS: Missing supportive care therapies (feeding tubes, ventilation)